Evidence map›Paper›PMID 32028950›Full record

SynthesisRespiratory research2020

Gender differences in pulmonary arterial hypertension patients with BMPR2 mutation: a meta-analysis.

Xiaoyue Ge, Tiantian Zhu, Xinyi Zhang, Ye Liu, Yonglong Wang, Weifang Zhang

Open access · goldAbstract readMeta-Analysis
In one paragraph

Synthesis in Respiratory research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.

  1. Pooled it
  2. Breast Cancer Reveals LatentCirculation · 2026
    Article
  3. Observational
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Xiaoyue GeDepartment of Pharmacy, The Second Affiliated Hospital of Nanchang University, Nanchang, 330006, China.
Tiantian ZhuTeaching and Research Office of Clinical Pharmacology, College of Pharmacy, Xinxiang Medical University, Xinxiang, 453003, China.
Xinyi ZhangDepartment of Pharmacy, The Second Affiliated Hospital of Nanchang University, Nanchang, 330006, China.
Ye LiuDepartment of Pharmacy, The Second Affiliated Hospital of Nanchang University, Nanchang, 330006, China.
Yonglong WangDepartment of Pharmacy, The Second Affiliated Hospital of Nanchang University, Nanchang, 330006, China.
Weifang ZhangDepartment of Pharmacy, The Second Affiliated Hospital of Nanchang University, Nanchang, 330006, China. z_weifang@163.com.
Nanchang University · CNXinxiang Medical University · CN

Funding

National Natural Science Foundation of China 81800051National Natural Science Foundation of China 81960015Youth Science Foundation from the Science and Technology Department of Jiangxi province 20161BAB215251Youth Science Foundation from the Science and Technology Department of Jiangxi province 20171BAB215002Youth Science Foundation from the Science and Technology Department of Jiangxi province 20171BAB215040
6 · The paper itself

Abstract

objectiveTo investigate the differences in the proportions of BMPR2 mutations in familial hereditary pulmonary arterial hypertension (HPAH) and idiopathic pulmonary arterial hypertension (IPAH) between males and females and the relationship between BMPR2 mutation and PAH severity.

methodsA computer was used to search the electronic Cochrane Library, PubMed/MEDLINE, and EMBASE databases for clinical trials containing information on the relationship between PAH prognosis and BMPR2 mutations through March 2019. After obtaining the data, a meta-analysis was performed using Review Manager Version 5.3 and Stata.

resultsA meta-analysis was performed on 17 clinical trials (2198 total patients: 644 male, 1554 female). The results showed that among patients with HPAH and IPAH, the BMPR2 mutation rate is higher in male than in female patients [male group (224/644, 34.78%), female group (457/1554, 29.41%), OR = 1.30, 95% CI: 1.06~1.60, P = 0.01, I

conclusionAmong patients with HPAH and IPAH, men are more likely to have BMPR2 mutations, which may predict more severe PAH indications and prognosis.

Indexed as

Sex CharacteristicsBone Morphogenetic Protein Receptors, Type IIClinical Trials as TopicFemaleHumansMaleMutationPulmonary Arterial HypertensionBMPR2 protein, humanBone Morphogenetic Protein Receptors, Type IIBMPR2 mutationsGenderMeta-analysisPulmonary arterial hypertension

Identifiers

PMID32028950
PMCPMC7006426
OpenAlexW3012662988

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.